SCHEMBL3069802

SCHEMBL3069802

CC(=O)/C=C(/C)NC1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 7/20 0.52
NPC1 O15118 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
RAB9A P51151 3/20 0.52
EPHX2 P34913 3/20 0.52
MAPT P10636 1/20 0.52
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52
CYP3A4 P08684 1/20 0.52
NPSR1 Q6W5P4 2/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
GAA P10253 1/20 0.46
MMP2 P08253 3/20 0.44
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
MMP8 P22894 1/20 0.44
MMP1 P03956 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3069805 1.00 EPHX1 (0.52) EPHX1NPC1SMN1; SMN2RAB9AEPHX2
SCHEMBL19066271 0.98 EPHX1 (0.48) EPHX1NPC1SMN1; SMN2RAB9AEPHX2
SCHEMBL19066273 0.98 EPHX1 (0.48) EPHX1NPC1SMN1; SMN2RAB9AEPHX2
SCHEMBL21647247 0.86 NPC1 (0.53) EPHX1NPC1SMN1; SMN2RAB9AEPHX2
SCHEMBL11055766 0.84 NPC1 (0.52) EPHX1NPC1SMN1; SMN2RAB9AEPHX2
SCHEMBL4381639 0.82 NPSR1 (0.49) EPHX1NPC1SMN1; SMN2RAB9AEPHX2
SCHEMBL4381636 0.82 NPSR1 (0.49) EPHX1NPC1SMN1; SMN2RAB9AEPHX2
SCHEMBL19621304 0.82 EPHX1 (0.50) EPHX1NPC1SMN1; SMN2RAB9AEPHX2
SCHEMBL10560424 0.80 NPSR1 (0.46) EPHX1NPC1SMN1; SMN2RAB9AEPHX2
SCHEMBL10560406 0.80 NPSR1 (0.46) EPHX1NPC1SMN1; SMN2RAB9AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108473618-B Process for preparing solid catalyst component for polymerization and copolymerization of ethylene SABIC环球技术有限责任公司 2024-01-09 CN claimed
EP-3397660-B1 PROCESS FOR MAKING A SOLID CATALYST COMPONENT FOR ETHYLENE POLYMERIZATION AND COPOLYMERIZATION SABIC GLOBAL TECHNOLOGIES BV (NL) 2023-04-26 EP claimed
US-10730965-B2 Process for making a solid catalyst component for ethylene polymerization and co-polymerization SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2020-08-04 US claimed
EP-3397662-B1 PROCESS FOR MAKING A SOLID CATALYST COMPONENT FOR ETHYLENE POLYMERIZATION AND COPOLYMERIZATION SABIC GLOBAL TECHNOLOGIES BV (NL) 2019-09-11 EP claimed
US-20190153126-A1 PROCESS FOR MAKING A SOLID CATALYST COMPONENT FOR ETHYLENE POLYMERIZATION AND CO-POLYMERIZATION SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2019-05-23 US claimed
US-20180371115-A1 PROCESS FOR MAKING A SOLID CATALYST COMPONENT FOR ETHYLENE POLYMERIZATION AND CO-POLYMERIZATION SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2018-12-27 US claimed
EP-3397660-A1 PROCESS FOR MAKING A SOLID CATALYST COMPONENT FOR ETHYLENE POLYMERIZATION AND COPOLYMERIZATION SABIC Global Technologies B.V. (NL) 2018-11-07 EP claimed
WO-2017114784-A1 PROCESS FOR MAKING A SOLID CATALYST COMPONENT FOR ETHYLENE POLYMERIZATION AND COPOLYMERIZATION SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2017-07-06 WO claimed
US-4042646-A BETA-AMINO-ALPHA, BETA-UNSATURATED KETONE, POLYESTERS NIHON YUSHI CO., LTD. (JA) 1977-08-16 US claimed
US-12582970-B2 Inorganic solid silicon-based sulfonic acid and/or phosphoric acid catalyst, preparation method therefor, and application thereof XIANGTAN UNIVERSITY (CN) 2026-03-24 US disclosed
CN-108473618-B Process for preparing solid catalyst component for polymerization and copolymerization of ethylene SABIC环球技术有限责任公司 2024-01-09 CN disclosed
EP-3397660-B1 PROCESS FOR MAKING A SOLID CATALYST COMPONENT FOR ETHYLENE POLYMERIZATION AND COPOLYMERIZATION SABIC GLOBAL TECHNOLOGIES BV (NL) 2023-04-26 EP disclosed
US-20230104925-A1 INORGANIC SOLID SILICON-BASED SULFONIC ACID AND/OR PHOSPHORIC ACID CATALYST, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF XIANGTAN UNIVERSITY (CN) 2023-04-06 US disclosed
EP-4119223-A1 INORGANIC SOLID SILICON-BASED SULFONIC ACID AND/OR PHOSPHORIC ACID CATALYST, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Xiangtan University (CN) 2023-01-18 EP disclosed
US-20030234063-A1 Non-toxic corrosion-protection conversion coats based on cobalt DAYTON, UNIVERSITY OF 2003-12-25 US disclosed
US-20030230363-A1 Non-toxic corrosion-protection rinses and seals based on cobalt UNIVERSITY OF DAYTON 2003-12-18 US disclosed
WO-2003060192-A1 NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT UNIVERSITY OF DAYTON (US) 2003-07-24 WO disclosed
WO-2003060191-A2 NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT UNIVERSITY OF DAYTON (US) 2003-07-24 WO disclosed
WO-2003060019-A1 NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT UNIVERSITY OF DAYTON (US) 2003-07-24 WO disclosed
US-4042646-A BETA-AMINO-ALPHA, BETA-UNSATURATED KETONE, POLYESTERS NIHON YUSHI CO., LTD. (JA) 1977-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12582970-B2 Inorganic solid silicon-based sulfonic acid and/or phosphoric acid catalyst, preparation method therefor, and application thereof STS, TST, HAO2 EPHX1 1024/4885NPC1 1647/4885SMN1; SMN2 1706/4885
US-20230104925-A1 INORGANIC SOLID SILICON-BASED SULFONIC ACID AND/OR PHOSPHORIC ACID CATALYST, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF SOAT1, SOAT2, WASF2 EPHX1 1448/4885NPC1 2545/4885SMN1; SMN2 2629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.